You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 104 No. 3, March 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (38)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Reduction of Pupillary Constriction During Cataract Surgery Using Suprofen

Walter J. Stark, MD; Warren R. Fagadau, MD; Robert H. Stewart, MD; Alan S. Crandall, MD; Joseph M. deFaller; Troy A. Reaves, Jr, PhD; Pamela Edwards Klein, MEd

Arch Ophthalmol. 1986;104(3):364-366.


Abstract

• The efficacy of a new nonsteroidal anti-inflammatory agent, suprofen, for reducing pupillary constriction during cataract surgery was ascertained in a double-masked, multicenter, clinical study. Prior to surgery 1.0% suprofen or a placebo was instilled; the surgeon's normal regimen of mydriatics and cycloplegics was used. Suprofen (209 patients) was far more effective than the placebo (203 patients) in maintaining a dilated pupil prior to intraocular lens (IOL) implantation (or instillation of a miotic). The mean pupillary area prior to IOL implantation was 6.3 sq mm larger (20% larger) in patients treated with suprofen than in patients receiving the placebo. The investigators' subjective evaluations of the adequacy of pupil size for IOL implantation and of the difficulty of IOL implantation favored patients treated with suprofen over those receiving the placebo.



Author Affiliations

From the Wilmer Institute, Johns Hopkins Hospital, Baltimore (Dr Stark and Ms Klein); Dallas Ophthalmology Center (Dr Fagadau); Conner Glaucoma Center, The University of Texas Science Center, Houston (Dr Stewart); Division of Ophthalmology, University of Utah Medical Center, Salt Lake City (Dr Crandall); and the William C. Conner Research Center, Alcon Laboratories Inc, Fort Worth, Tex (Mr deFaller and Dr Reaves).


Footnotes

Accepted for publication Oct 18, 1985.

Reprint requests to the Wilmer Institute, Maumenee 327, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21205 (Dr Stark).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical 0.5% Ketorolac vs 0.03% Flurbiprofen for Inhibition of Miosis During Cataract Surgery
Solomon et al.
Arch Ophthalmol 1997;115:1119-1122.
ABSTRACT  

The Prethreaded Pupillary Dilating (Torpedo) Suture for Phakic and Aphakic Eyes
Freeman et al.
Arch Ophthalmol 1992;110:564-567.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.